Awareness of rabies prevention and control is driving significant trends and advances in the rabies diagnostics industry. This industry must diagnose and manage the deadly virus, hence effective and efficient diagnostic tools are needed.
The market is driven by rising global rabies rates. Rabies incidence are rising, particularly in developing countries, highlighting the need for precise and fast diagnoses to control the illness.
Rapid and precise rabies testing are achievable due to technology. Since PCR and nucleic acid amplification are more precise and quicker than previous procedures, they are becoming more popular.
Rabies veterinary diagnostics are in high demand, boosting the sector. Rabies may be carried from animals to humans, thus early diagnosis is crucial to protecting animals and people. Cattle may get rabies from animals.
Point-of-care tests provide fast diagnosis without sophisticated laboratory equipment, making them increasingly popular. This propensity is crucial for timely intervention and management in remote areas where centralized laboratories may be unavailable.
Alarmingly, diagnostic firms, research institutions, and government organizations are collaborating more. These collaborations will boost research and development, leading to more efficient and accessible rabies diagnostic technology.
Rabies control is becoming increasingly important to governments worldwide, resulting in higher investment on diagnostic facilities and awareness programs. Combining these actions with vaccine programs creates a comprehensive viral prevention approach.
Rabies is common in emerging countries, where the market is expanding to reach more individuals. Growth is enabled by strategic market players targeting these places to satisfy unmet diagnostic needs and improve sickness management.
Serological testing for rabies is becoming increasingly widespread, especially for post-exposure prophylactic surveillance. These tests help determine vaccination efficacy and guide medical treatment by revealing the immune response.
Rabies diagnostic kit licensing and marketing are heavily regulated, which affects the market. Compliance with these principles builds confidence in healthcare professionals and patients by making diagnostic equipment safe and effective.
Rabies diagnostics is consolidating because to major companies merging and acquiring to increase their product ranges. The present competitive climate encourages diagnostic innovation and improvement.
Educational activities and community participation projects are raising public awareness and aiding rabies diagnosis. Due to exposure concerns, patients seek quick medical help, increasing diagnostic demand.
Rabies Diagnostics Market OverviewÂ
Rabies Diagnostics Market Segmentation
The global rabies diagnostics market has been segmented on the basis of method, technology, end-user, and region.
On the basis of method, the market has been classified as a fluorescent antibody test (FAT), immunohistochemical test, amplification methods, histologic examination, and serology tests. Also, by technology, the market has been segmented into ELISA/immunohistochemistry, chromatography techniques, PCR, and others.
Based on market has been divided into hospitals, diagnostic centers, cancer palliative care clinics, and others. By end-user hospitals are likely to register the highest CAGR owing to the rising prevalence of rabies in emerging countries during the forecast period.
The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The rabies diagnostics market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.
The European rabies diagnostics market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.Â
The market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The market in the Middle East & Africa has been segmented into the Middle East and Africa.
Global Rabies Diagnostics Market Share, by Region, 2017 (%)
Source: MRFR Analysis
Asia-Pacific is likely to dominate the rabies diagnostics market during the forecast period owing to the improving healthcare infrastructure, rising investments in healthcare and expansions by market players in the region. Also, countries such as India and China are considering the fastest growing region due to a government focused toward adopting new technology and the best treatment option from a developed country. According to the World Health Organization, in 2010, the healthcare expenditure of India was 3.27% of GDP, whereas, in 2015 it has 3.89% of total GDP.
The Americas are likely to be the second-largest market in the global rabies diagnostics market owing to the rising strategic alliance by major players, increasing awareness about rabies, the involvement of non-profit organization to control rabies, and well-established healthcare infrastructure. According to the American Pet Products Association's 2017-2018 National Pet Owners Survey, Number of animals in the American region is increasing, and there were around 60.2 million dogs, and47.1pet cats were present in the Americas.Â
The European market is expected to hold a significant share in the rabies diagnostics market. The market growth in this region can be attributed to the government funding, well-established healthcare sector, and support of the healthcare sector coupled with increasing research and development.
The market in the Middle East & Africa is expected to account for the smallest share of the global rabies diagnostics market due to an underdeveloped healthcare sector, lack of technical knowledge, and poor medical facilities.
Rabies Diagnostics Market Key Players
Some of the key players in the global market are Bio-Rad Laboratories, Inc., Merck KGaA, Aviva Systems Biology Corporation, Creative Diagnostics, Demeditec Diagnostics GmbH, Abbexa Ltd., Norgen Biotek Corp., BioNote, Inc., Express Biotech International Inc., MyBioSource.com., and BioGen Technologies
Global Rabies Diagnostics Market, by Method
Global Rabies Diagnostics Market, by Technology
Global Rabies Diagnostics Market, by End User
Global Rabies Diagnostics Market, by Region
Company Profiles
In April 2022
Cadila Pharmaceuticals announced that it had developed the world's first novel three-dose vaccine against rabies. The three-dose vaccine, named 'ThRabis,' is a recombinant nano-particle-based G protein vaccine prepared using Virus-like Particle technology.
The company added that the three-dose schedule is spread over one week.
The new vaccine will prove to be a game-changer because all the other rabies vaccines require five injections over 28 days to eliminate the threatCadila, Pharmaceuticals said at the launch ceremony of the new vaccine.
Intended Audience
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)